Suggested remit: To appraise the clinical and cost effectiveness of icosapent ethyl within its marketing authorisation for preventing cardiovascular events due to elevated triglycerides.
 
Status In progress
Process STA 2018
ID number 3831

Provisional Schedule

Committee meeting 13 October 2021
Expected publication 05 January 2022

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd

Consultees

Companies sponsors Amarin Corporation (Icosapent ethyl)
Others Department for Health and Social Care
  NHS England
  NHS Nottingham City CCG
  NHS Southwark CCG
  Welsh Government
Patient carer groups Arrythmia Alliance
  Atrial Fibrillation Association
  Blood Pressure UK
  Cardiac Risk in the Young
  Cardiomyopathy UK
  Cardiovascular Care Partnership
  Circulation Foundation
  Different Strokes
  Genetic Alliance
  HEART UK
  Network of Sikh Organisations
  Pumping Marvellous Foundation
  Somerville Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Stroke Association
  Stroke Information
Professional groups Association of Genetic Nurses and Counsellors
  British Association for Nursing in Cardiovascular Care
  British Association of Stroke Physicians
  British Atherosclerosis Society
  British Cardiovascular Intervention Society
  British Cardiovascular Society
  British Geriatrics Society
  British Heart Foundation
  British Heart Rhythm Society
  British Nuclear Cardiology Society
  British Society for Gene and Cell Therapy
  British Society for Genetic Medicine
  British Society for Haematology
  British Society for Haemostasis and Thrombosis
  British Society for Heart Failure
  British Society for Human Genetics
  British Society of Cardiovascular Imaging
  Clinical Leaders of Thrombosis
  National Heart and Lung Institute
  Royal College of Emergency Medicine
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society for Cardiological Science and Technology
  Society for Vascular Nurses
  Society for Vascular Technology
  UK Clinical Pharmacy Association
  UK Genetic Testing Network
  Vascular Society of Great Britain and Ireland

Commentators

Associated guideline groups National Guideline Alliance
Associated public health groups Public Health England
  Public Health Wales
Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups British Society for Cardiovascular Research
  Cardiac and Cardiology Research Dept, Barts
  Cochrane Heart Group
  Cochrane Stroke Group
  Cochrane Vascular
  European Council for Cardiovascular Research
  MRC Clinical Trials Unit
  National Centre for Cardiovascular Prevention and Outcomes
  Heart Research UK
  National Institute for Health Research
  Society for Research in Rehabilitation
  Wellcome Trust

Timeline

Key events during the development of the guidance:

Date Update
15 February 2021 Invitation to participate
15 February 2021 In progress. In progress.
25 September 2020 - 23 October 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance